46 results on '"Compernolle, Griet"'
Search Results
2. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
3. Prediction and Reduction of the Aggregation of Monoclonal Antibodies
4. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
5. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
6. Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
7. Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
8. Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time
9. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1
10. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis
11. Mo1559: USTEKINUMAB EXPOSURE AFFECTS REAL-WORLD ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN ULCERATIVE COLITIS
12. Development of an immunological toolbox to detect endogenous and exogenous pectin methylesterase in plant-based food products
13. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays
14. Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences
15. Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis
16. Site-directed Targeting of Plasminogen Activator Inhibitor-1 as an Example for a Novel Approach in Rational Drug Design
17. Immobilization of the Distal Hinge in the Labile Serpin Plasminogen Activator Inhibitor 1: IDENTIFICATION OF A TRANSITION STATE WITH DISTINCT CONFORMATIONAL AND FUNCTIONAL PROPERTIES
18. Supplemental material for Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
19. Anti-infliximab antibodies: How to compare old and new data?
20. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
21. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
22. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study
23. Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
24. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
25. Golimumab Trough Levels Predict Mucosal Healing and Success of Dose Optimization: A Prospective Observational Study
26. Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease
27. Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment
28. Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn's Disease Losing Clinical Response
29. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
30. Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA
31. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases
32. Sa1916 - Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn's Disease Losing Clinical Response
33. Sa1883 - Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment
34. Sa1878 - Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease
35. Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
36. Sa1248 TNF-Responsive Cellular Based Assay Reveals Neutralizing Capacity of Anti-Adalimumab Antibodies in Crohn's Disease and Ulcerative Colitis Patients
37. O-003 YI Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy In IBD
38. 1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial
39. Crohn's Disease: Infliximab Trough Levels and CRP During Infliximab-Immunomodulator Combination Treatment Are Associated With Clinical Outcome After Immunomodulator Withdrawal
40. Early Trough Levels and Antibodies Predict Safety and Success of Restarting Infliximab After Long Drug Holiday
41. 407 Anti-TNFα Induced Severe Arthralgia as a Manifestation of Autoimmunity?
42. 405 High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease
43. Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)
44. Biochemical Importance of Glycosylation in Thrombin Activatable Fibrinolysis Inhibitor
45. Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition
46. Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.